Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.31 |
| ▸ | CTSE | P14091 | 6/20 | 0.31 |
| ▸ | BACE1 | P56817 | 4/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16580104 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24047111 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL20800137 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL25295471 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24036409 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL23900253 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24092997 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL24047110 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL22661595 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 | |
| SCHEMBL19387543 | 1.00 | SSTR2 (0.46) | SSTR2CYP3A4FOLH1TTRKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364254-A1 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-3409287-B9 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2017008169-A1 | DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS | ZYMEWORKS INC. (CA) | 2017-01-19 | — | — | WO | disclosed |
| US-20150238633-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20120141509-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238633-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | SSTR2 4444/4885CYP3A4 3333/4885FOLH1 264/4885 |
| US-20120141509-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | SSTR2 3233/4885CYP3A4 1021/4885FOLH1 237/4885 |
| US-20230364254-A1 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | NECTIN4, CD2BP2, CD22 | SSTR2 2842/4885CYP3A4 3390/4885FOLH1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.